The anabolic catabolic transforming agent (ACTA) espindolol increases muscle mass and decreases fat mass in old rats
about
Cardiac cachexia: hic et nuncLoss of muscle mass: current developments in cachexia and sarcopenia focused on biomarkers and treatmentAnnual banned-substance review: analytical approaches in human sports drug testing.Deranged iron status in psoriasis: the impact of low body mass.Espindolol for the treatment and prevention of cachexia in patients with stage III/IV non-small cell lung cancer or colorectal cancer: a randomized, double-blind, placebo-controlled, international multicentre phase II study (the ACT-ONE trial).Developing models for cachexia and their implications in drug discovery.Pharmacologic Options for the Treatment of Sarcopenia.Establishment and characterization of a novel murine model of pancreatic cancer cachexia.Evidence for partial pharmaceutical reversal of the cancer anorexia-cachexia syndrome: the case of anamorelin.Publication trends in cachexia and sarcopenia in elderly heart failure patients.Pathogenesis and Management of Sarcopenia.Megestrol acetate improves cardiac function in a model of cancer cachexia-induced cardiomyopathy by autophagic modulation.Moving upwards - the journal of cachexia, sarcopenia and muscle in 2016.Therapeutic considerations of sarcopenia in heart failure patients.Muscle wasting and sarcopenia in heart failure and beyond: update 2017.
P2860
Q26744140-7B48105A-8CF3-4FD3-A888-8B0019F148EEQ26775254-A9283B62-9215-4143-9BFD-4916287261E5Q34509038-8BA3477F-D249-4987-9CB5-43F42E5FAB4BQ36349371-4C62A008-471D-401B-A10A-FC75C5B8DF48Q37057905-53B2ED52-A044-4D7B-B8E8-A5177ECE0136Q38451282-A4B2394A-7A0C-49AC-B5BA-8028B8D56B26Q38534875-B6BC0317-9493-4718-9951-04E43A5074A6Q38653925-4811B522-1223-48A5-9363-84657A736ED2Q38931233-940539F3-D2EF-4E59-967C-A44FB6E246E2Q39019268-02F58F58-A4B9-40E0-92D9-F5E905F02EA9Q39019596-6ADAEE90-DE84-45E0-9046-4CEE29800BA1Q39726480-754FA55C-B625-44B2-A656-01AE2FF118DBQ42398018-A1156311-8EA1-41D0-A616-13CFDC9DBEC6Q47747144-8D8797E5-622C-4999-9DF9-9C64B6D85B5EQ49183956-3AF755F9-0FD7-404C-A278-6753CDCF1AE1
P2860
The anabolic catabolic transforming agent (ACTA) espindolol increases muscle mass and decreases fat mass in old rats
description
2014 nî lūn-bûn
@nan
2014 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
The anabolic catabolic transfo ...... decreases fat mass in old rats
@ast
The anabolic catabolic transfo ...... decreases fat mass in old rats
@en
The anabolic catabolic transfo ...... decreases fat mass in old rats
@nl
type
label
The anabolic catabolic transfo ...... decreases fat mass in old rats
@ast
The anabolic catabolic transfo ...... decreases fat mass in old rats
@en
The anabolic catabolic transfo ...... decreases fat mass in old rats
@nl
prefLabel
The anabolic catabolic transfo ...... decreases fat mass in old rats
@ast
The anabolic catabolic transfo ...... decreases fat mass in old rats
@en
The anabolic catabolic transfo ...... decreases fat mass in old rats
@nl
P2093
P2860
P3181
P1476
The anabolic catabolic transfo ...... decreases fat mass in old rats
@en
P2093
Andrew J S Coats
Anika Tschirner
Jochen Springer
John Beadle
Mareike S Pötsch
Sandra Palus
Wolfram Doehner
P2860
P2888
P304
P3181
P356
10.1007/S13539-013-0125-7
P407
P577
2014-06-01T00:00:00Z
P5875
P6179
1025095233